PTC THERAPEUTICS, INC. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2023 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Ptc Therapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2023 to Q1 2024.
  • Ptc Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$1K, a 75% increase year-over-year.
  • Ptc Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$46.9M, a 36.8% decline from 2022.
  • Ptc Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$34.3M, a 9192% decline from 2021.
  • Ptc Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $377K, a 93.6% decline from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$1K +$3K +75% Jan 1, 2024 Mar 31, 2024 10-Q 2024-04-25
Q2 2023 -$50.9M May 1, 2023 May 31, 2023 10-Q 2023-10-26
Q1 2023 -$4K Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.